Citron Research's Left: Mallinckrodt 'not a pharmaceutical company'

Citron Research, the short-selling firm that set off scrutiny about Valeant Pharmaceuticals' business model, sent Mallinckrodt shares lower Monday by tweeting that the company had "more downside" than Valeant at its current price. We already see these challenges at Mallinckrodt and while Valeant has been taking all the heat, the business model of...